Where does Ultragenyx Pharmaceutical's cash flow data come from?

Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$608.92M-10.9%	-$574.92M-1.0%	-$579.57M-3.6%	-$532.67M+9.0%	-$549.32M+10.5%
Depreciation and amortization	$34M-6.0%	$35M-2.8%	$35.75M+3.1%	$35.9M+8.4%	$36.16M+22.1%
Change in accounts receivable	$22M—	$31M—	$18.21M—	——	——
Change in inventories	——	——	——	——	$9.88M+6.5%
Other working capital changes	——	——	——	——	——
Change in deferred revenue	——	——	——	——	——
Net cash from operating activities	-$497M-27.7%	-$466M-12.6%	-$445.49M-6.4%	-$421.06M+10.3%	-$389.27M+23.5%
Capital expenditures	$6M+25.3%	$6M-14.3%	$5.23M-36.0%	$5.56M-45.7%	$4.79M-78.4%
Purchases of investments	$317M-18.1%	$186M-54.5%	$48.77M-92.1%	$399.2M+3.4%	$387.07M-20.3%
Proceeds from maturities/sales of investments	——	——	——	——	$137.3M+218%
Purchases of intangible assets	——	——	——	——	$18M+38.5%
Other investing activities	——	——	——	——	——
Net cash from investing activities	——	——	——	——	——
Effect of exchange rate changes on cash	——	——	$2.71M—	——	——
Net increase (decrease) in cash	$50M—	$252M—	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$3M-73.3%	$4M-69.2%	$6.67M-52.1%	$9.08M-32.7%	$11.24M-18.3%
Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost	$143M-11.2%	$153M-3.2%	$155.85M+2.9%	$160.15M+10.7%	$161.07M+15.1%
Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities	$15M-56.6%	$24M-48.9%	$33.38M—	-$925K—	$34.54M—
Prepaid expenses and other current assets	——	——	——	$4.45M+163%	$11.28M+163%
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties	$68.66M+12.3%	$61.66M-2.1%	$57.67M-11.1%	$59.23M-11.3%	$61.15M-7.6%
Non Cash Royalty Revenue	$113M+10.9%	$112M+10.9%	$108.01M+15.3%	$106.16M+16.4%	$101.94M+24.0%
Other Noncash Income (Expense)	——	——	——	——	——
Payment for (Proceeds from) Other Investing Activity	——	——	——	——	——
Payments to Acquire Intangible Assets	——	——	——	——	$18M+38.5%
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$395M-5.5%	$444M+8.3%	$481.21M+19.0%	$439.19M-9.6%	$418.21M-34.0%
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	——	——	$2.71M—	——	——
Free cash flow	-$503M-27.6%	-$472M-12.1%	-$450.71M-5.6%	-$426.62M+11.1%	-$394.06M+25.8%
Free cash flow	-$503M-27.6%	-$472M-12.1%	-$450.71M-5.6%	-$426.62M+11.1%	-$394.06M+25.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Ultragenyx Pharmaceutical's cash flow data come from?: Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.